

Isabella Moreau Bullet Point Update

- **Pt:** Moreau, Isabella C (MRN: SYN072)
- **DOB:** 07/18/1971 (52y fem)
- **Dx:** March 23 Stage IV Lung Adeno, EGFR L858R+, PDL1 neg. Mets to bone only.
- **Rx:** Osimertinib 80mg QD (since 03/10/23) + Denosumab 120mg SC monthly.
- **Date:** 08/21/2023
- **Visit Type:** Routine F/U (~5.5 mos Rx)
- **S:** Feels great. No bone pain/sx. Tolerating Osi well - Gr 1 dry skin elbows, Gr 1 brittle nails only. No diarrhea/rash/stomatitis. ECOG 0. Adherent.
- **O:** Vitals WNL. Exam unremarkable except mild xerosis elbows. Labs WNL (CBC/CMP/Mg/Ca). CT C/A/P (08/08/23): Stable PR, bone mets sclerotic/responding. Brain MRI surveillance neg.
- **A:** Excellent ongoing response to 1L Osimertinib + Denosumab. Minimal toxicity.
- **P:**
 - Cont Osi 80mg QD.
 - Cont Denosumab monthly + Ca/D.
 - Next labs/clinic F/U in 3 mos.
 - Next CT C/A/P ~Nov 2023.
 - Next Brain MRI ~Oct 2023.
 - Continue supportive care (emollients). RTC sooner PRN issues.
- **Provider:** E. Reed, MD, PhD